Cantargia logo

Cantargia Investor Relations Material

Cantargia AB, a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. Its lead product is CAN04, an antibody directed the interleukin-1 receptor accessory protein that targets cancer cells that express IL1RAP on their surface; and CAN04 is currently being developed in two clinical programs, one focusing on treatment of lung cancer and another on treatment of pancreatic cancer. Cantargia AB was founded in 2010 and is based in Lund, Sweden

Upcoming events for

Q2 20222022-08-18

Latest company events

Ticker symbol




About the company

Dig deeper into the Cantargia fundamentals on Quartr.

  • Skip straight to the Q&A session
  • Receive notifications about new events
  • Connect the financial calender on your phone
  • Figure out why the stock is up or down
  • Read the transcripts or scroll the deck
  • Access earnings or press releases
App store link
Android play link
Quartr app screenshot